Onvansertib was reported to exert antitumor activity in combination with the microtubule depolymerization inhibitor paclitaxel in mucinous ovarian cancer and HGOC [49] with abiraterone, due to its androgen receptor-independent effects on mitotic spindle in castrate-resistant prostate cancer models [29], and with the microtubule-targeting agents vincristine, vinblastine and eribulin in Ewing sarcoma [50]. Here, AR is linked to Familial prostate cancer.